Background: Atezolizumab, one of the immune checkpoint inhibitors, has been approved as an adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II-IIIA non-small cell lung cancer with 1% or more programmed death ligand-1 (PD-L1) expression. The Food and Drug Administration (FDA) has approved SP263 as a companion diagnostic assay for adjuvant treatment with atezolizumab; however, in clinical practice, the 22C3 assay is most commonly used for advanced non-small cell lung cancer. Therefore, our study aimed to compare two PD-L1 assays, SP263 and 22C3, to evaluate whether 22C3 could replace SP263 when deciding whether to administer adjuvant atezolizumab.
Methods: We retrospectively and prospectively analyzed 98 patients who underwent surgical resection at Kanagawa Cancer Center (Japan). An immunohistochemistry assay was performed for all the cases with both SP263 and 22C3. We statistically analyzed the concordance of PD-L1 expression between SP263 and 22C3 assays.
Results: The concordance between the two assays using Cohen's kappa was κ = 0.670 (95% CI: 0.522-0.818) at the 1% cutoff and κ = 0.796 (95% CI: 0.639-0.954) at the 50% cutoff. The Spearman correlation coefficient of 0.874 (p < 0.01) indicated high concordance. PD-L1 expression with 22C3 resulted slightly higher than that with SP263.
Conclusions: This study showed a high concordance of PD-L1 expression with the SP263 and 22C3 assays. Further studies examining the therapeutic effects of adjuvant atezolizumab are required.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11168908 | PMC |
| http://dx.doi.org/10.1111/1759-7714.15319 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Expression of PD-L1 in breast invasive lobular carcinoma.
PLoS One
October 2024
Department of Pathology, Yonsei University College of Medicine, Seoul, South Korea.
Article Synopsis
- - The study aimed to explore PD-L1 expression in invasive lobular carcinoma (ILC) and its potential implications for cancer treatment.
- - Researchers created tissue arrays from 101 ILC cases and used immunohistochemical staining to analyze PD-L1 levels, finding that tumor cell positivity was low (0-2%) and immune cell positivity varied significantly (0-21.8%).
- - Higher PD-L1 expression in immune cells was linked to factors like nuclear grade and HER-2 positivity, suggesting that certain types of ILC, particularly the pleomorphic type, may have more significant PD-L1 involvement.
Comparison of PD-L1 assays in head and neck carcinoma.
Pathology
December 2024
Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. Electronic address:
Article Synopsis
- PD-L1 expression serves as a crucial biomarker in predicting how patients with head and neck squamous cell carcinoma might respond to immune checkpoint inhibitors, making it important to evaluate different testing methods.
- A study conducted at Asan Medical Center evaluated PD-L1 expression in 156 cases using various standardized assays and a laboratory-developed test, revealing good to excellent agreement among the methods.
- The results highlighted that PD-L1 expression significantly varies with tumor location and suggests that the different assays could potentially be used interchangeably for assessing PD-L1 in head and neck cancers.
CD68 positive and/or CD163 positive tumor-associated macrophages and PD-L1 expression in breast phyllodes tumor.
Breast Cancer Res Treat
September 2024
Department of Pathology, Yonsei University College of Medicine, Seoul, South Korea.
Article Synopsis
- This study focused on the expression of PD-L1 and tumor-associated macrophages (TAMs) in phyllodes tumors (PT) of the breast, an area with limited previous research.
- Researchers constructed tissue microarrays from 181 PT samples and used specific antibodies to analyze PD-L1 and TAM markers, correlating findings with clinical parameters.
- Results showed higher levels of CD68- and CD163-positive TAMs in more aggressive PTs, with significant correlations to PD-L1 expression, suggesting that these markers could be important for understanding tumor behavior and patient outcomes.
The prognostic value of programmed death-ligand 1 (PD-L1) expression in resected colorectal cancer without neoadjuvant therapy - differences between antibody clones and cell types.
BMC Cancer
August 2024
Department of Clinical Sciences Lund, Division of Pathology, Lund University, Lund, Sweden.
Background: Programmed death-ligand 1 (PD-L1) expression on tumor cells is associated with poor prognosis in several malignancies, while partly contradictory and inconclusive results have been presented for colorectal cancer (CRC). This study aimed to evaluate PD-L1 as a prognostic biomarker in CRC by comparing three different antibody clones.
Methods: Patients surgically treated for CRC between January 1st, 2007, and December 31st, 2015, in Kalmar County, Sweden, were retrospectively included.
Programmed death-ligand 1 expression in carcinoma of unknown primary.
BMC Cancer
June 2024
Department of Pathology, Yonsei University College of Medicine, Seoul, South Korea.
Article Synopsis
- - The study focused on the expression of PD-L1 in carcinoma of unknown primary (CUP) by analyzing tissue samples from 72 cases, using various immunohistochemical methods.
- - The PD-L1 positivity rates in CUP varied significantly depending on the antibodies used, with rates ranging from 5.6% to 48.6%, but these rates did not change with different histologic or clinical subtypes.
- - Analysis showed that while PD-L1 expression was inconsistent across various scoring systems, there was a fair level of agreement between different antibodies used in the study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!